Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing
Targeted therapies have made near normal life span an attainable goal for many patients with chronic phase (CP) chronic myeloid leukemia (CML). Most patients require years of therapy and not everyone may be able to discontinue treatment permanently without CML recurrence. BCR::ABL1 targeted tyrosin...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Ferrata Storti Foundation
2026-03-01
|
| Serija: | Haematologica |
| Online pristup: | https://haematologica.org/article/view/13384 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|